Presentation is loading. Please wait.

Presentation is loading. Please wait.

Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple.

Published byLauren Summers Modified over 5 years ago

Similar presentations

Presentation on theme: "Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple."— Presentation transcript:

1 Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple sclerosis. Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple sclerosis. A total of 40 people were included in the final analysis, and reasons for not receiving the allocated intervention (cocoa drink) and discontinuation are presented. Shelly Coe et al. J Neurol Neurosurg Psychiatry 2019;90: ©2019 by BMJ Publishing Group Ltd

Download ppt "Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple."

Similar presentations

Why double blind, controlled randomized trials?

Why double blind, controlled randomized trials?
Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Clinical correlates of neurodegeneration in MS
Sensory neuronopathy caused by dorsal root ganglionitis showing a hypercellular cluster of lymphocytes (nodule of Nageotte) indicating active neuronophagia.

Sensory neuronopathy caused by dorsal root ganglionitis showing a hypercellular cluster of lymphocytes (nodule of Nageotte) indicating active neuronophagia.
REFLEX and REFLEXION study design.

REFLEX and REFLEXION study design.
(A) This 54 year old man with the flail arm syndrome has severe wasting of the arms causing profound weakness. (A) This 54 year old man with the flail.

(A) This 54 year old man with the flail arm syndrome has severe wasting of the arms causing profound weakness. (A) This 54 year old man with the flail.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.
Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.

Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.
(A) EEG of a 75 year old woman with adult onset myoclonic epilepsy (see text, case 1), showing generalised spike and wave and polyspike and wave discharges.

(A) EEG of a 75 year old woman with adult onset myoclonic epilepsy (see text, case 1), showing generalised spike and wave and polyspike and wave discharges.
SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.

SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.
 Pseudoptosis.  Pseudoptosis. This man presented with photophobia and difficulty elevating the right side of his forehead. The photograph shows his normal.

 Pseudoptosis.  Pseudoptosis. This man presented with photophobia and difficulty elevating the right side of his forehead. The photograph shows his normal.
Cortical right hemisphere brain regions that have been associated with neglect include the angular (ang) and supramarginal (smg) gyri of the inferior parietal.

Cortical right hemisphere brain regions that have been associated with neglect include the angular (ang) and supramarginal (smg) gyri of the inferior parietal.
An example from a carotid surgery trial showing how an intention to treat analysis is less biased than an on-treatment analysis. An example from a carotid.

An example from a carotid surgery trial showing how an intention to treat analysis is less biased than an on-treatment analysis. An example from a carotid.
The parameters in the Reference Group model fit by EPP

The parameters in the Reference Group model fit by EPP
Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.
MILESTONE study flow diagram

MILESTONE study flow diagram
Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS 304801 Phase 2, randomised, double-blind, placebo-controlled study.

Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS Phase 2, randomised, double-blind, placebo-controlled study.
Reduction of muscle soreness after intervention, described as AUC of the difference after intervention minus before intervention for placebo and leucine.

Reduction of muscle soreness after intervention, described as AUC of the difference after intervention minus before intervention for placebo and leucine.
Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Similar presentations

Ads by Google